Belumosudil: A Rising Star for the Management of Chronic Graft-Versus-Host Disease and the First FDA-Approved ROCK2 Inhibitor
Year: 2021
Type: article
Source: The Hematologist
Authors: Tony J. Kurian, Frederick Locke
Institutions: University of South Florida, Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3206401689